The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Official Title: A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin(PLD)Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
Study ID: NCT03994107
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of pegylated liposomal doxorubicin(PLD)plus Albumin-Bound Paclitaxel and trastuzumab as neoadjuvant therapy in HER-2 positive breast cancer.
Detailed Description: This is a single-center, prospective, single arm phase II study. Eligible patients will receive neoadjuvant therapy with pegylated liposome doxorubicin (PLD)/albumin-bound paclitaxel/trastuzumab regimentation. This study consists of two phases, the first phase aims to determine the maximum tolerated dose (MTD) of PLD, and the second phase will explore the efficacy and safety of the regimen.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Fei Ma, Beijing, Beijing, China
Name: Fei Ma, MD
Affiliation: Cancer Hospital Chinese Academy of Medical Science
Role: PRINCIPAL_INVESTIGATOR